Citations

Showing 10 of 108104 citations.

Association of allergic disease with subsequent risk of liver cancer: A nation-wide cohort study
Kim, Ji Ah, Choi, Seulggie , Ahn, Joseph , Ahn, Joseph C , Chang, Jooyoung , Jeong, Seogsong , Lee, Gyeongsil , Son, Joung Sik , Park, Sang Min

Mayo Clinic

No container title available | February 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1287865/v1 Get It

Abstract Background : Studies have proposed an inverse association between allergic diseases and cancer risk, but few studies to date have specifically investigated the risk of primary liver cancer (hepatocellular carcinoma, HCC; intrahepatic cholangiocarcinoma, ICC) in patients with or without allergic diseases. Objective : The aim of this study was to evaluate the association between allergic diseases and risk of developing liver cancer.Methods: A retrospective cohort study of the Korean National Health Insurance Service database was performed to study 405,512 South Korean adults ages 40 and above who underwent routine health screening after January 1st, 2005. All participants were followed for liver cancer diagnosis or death until December 31st, 2013. Those who died before the index date, had pre-diagnosed cancer, or did not undergo health screening were excluded. Cox proportional hazards regression was performed to determine the adjusted hazard ratios(aHRs) and 95% confidence intervals (CIs) for risk of developing liver cancer according presence or absence of atopic dermatitis, asthma and allergic rhinitis.Results: The aHR (95% CI) for overall liver cancer among allergic patients was 0.72 (0.64-0.81). Allergic patients had significantly reduced risk of HCC (aHR: 0.70, 95% CI: 0.61-0.81) but not ICC (aHR: 0.99, 95% CI: 0.71-1.08). Presence of allergic diseases was associated with significantly lower risk of liver cancer in both patients with (aHR: 0.61, 95% CI: 0.47-0.8) or without (aHR: 0.74, 95% CI: 0.65-0.85) chronic Hepatitis B/C infections. Presence of allergic diseases was associated with significantly lower risk of liver cancer in patients without cirrhosis (aHR: 0.72, 95% CI 0.63-0.82), but not in those with cirrhosis (aHR: 0.98, 95% CI 0.68-1.41). Patients with multiple allergies had even lower risk of liver cancer compared to patients with single allergy. Conclusion: Patients with allergic diseases have significantly lower risk of developing liver cancer compared to those without allergic diseases, which supports the rationale for immunotherapy as an effective treatment of liver cancer.
Eye Movement Desensitization and Reprocessing in a Primary Care Setting: Assessing Utility and Comparing Efficacy of Virtual Versus In-Person Methods
Liou, Harris , Lane, Colton, Huang, Crystal , Mookadam, Martina , Joseph, Malin, DuVal, Jennifer Hecker, Hecker DuVal, Jennifer

Mayo Clinic

Telemedicine and e-Health | February 8, 2022 | Volume: 28 | Issue: 9 | Pages: 1359-1366

10.1089/tmj.2021.0454 | PMID 35133887 Get It

Introduction: Eye movement desensitization and reprocessing (EMDR) is an evidence-based psychotherapy method designed to treat distress associated with traumatic memories. The COVID-19 pandemic has challenged providers to shift EMDR to telehealth platforms. Objectives: This research had to aims. (1) To compare EMDR in conjunction with cognitive behavioral therapy (CBT) with CBT alone for treatment of a patient population with prevalent anxiety and (2) to compare the efficacy of virtual EMDR with that of in-person EMDR in the primary care setting. Methods: Retrospective chart review of all adult patients seen by a single therapist at a primary care center was conducted from January 2018 to December 2020. Charts were reviewed for demographics, psychiatric diagnoses, number of visits, number and type of EMDR treatments, and patient health questionnaire (PHQ)-9 and general anxiety disorder (GAD-7) scores pre- and post-treatment. Results: Patients who underwent EMDR with CBT demonstrated greater decreases in PHQ-9 and GAD-7 scores than patients who had only CBT (2.4, 2.5 vs. 0.9, 1.1). However, after adjusting for total number of sessions, post-traumatic stress disorder, grief, and pain, the adjusted mean differences of change in PHQ-9 and GAD-7 scores between those who underwent EMDR with CBT and CBT-exclusive patients were not statistically significant. Similarly, the adjusted mean differences of change in PHQ-9 and GAD-7 scores between those who underwent virtual EMDR and those who had in-person EMDR were not statistically significant. Conclusions: To our knowledge, this is the first study describing the use of virtual EMDR in a primary care setting. Although our data did not provide evidence for the superiority of EMDR with CBT over CBT alone, we demonstrate that both in-person and virtual EMDR led to significantly improved GAD-7 scores.
Immunotherapy as a Downstaging Tool for Liver Transplantation in Hepatocellular Carcinoma
Mathur, Amit K. , Borad, M.J., Lam‐Himlin, Dora , Corey, Rebecca, Iqbal, Sara , Okubo, Keita , Byrne, Thomas , Moss, Adyr A. , Aqel, Bashar , Chascsa, David M. , Lizaola-Mayo, Blanca C, Lam-Himlin, Dora M, Corey, Rebecca L, Byrne, Thomas J., Lizaola‐Mayo, Blanca , Jadlowiec, Caroline C. , Iqbal, Sara, Aqel, Bashar A.

Mayo Clinic

American Journal of Gastroenterology | February 8, 2022 | Volume: 116 | Issue: 12 | Pages: 2478-2480

10.14309/ajg.0000000000001391 | PMID 35134013 Get It

Reflections on Our Editorship of The American Journal of Gastroenterology
Spiegel, Brennan , Lacy, Brian E. , Spiegel, Brennan , Lacy, Brian E.

Mayo Clinic

American Journal of Gastroenterology | February 8, 2022 | Volume: 116 | Issue: 12 | Pages: 2313-2315

10.14309/ajg.0000000000001558 | PMID 35134007 Get It

Diagnostic Evaluation of Gastric Motor and Sensory Disorders
Lacy, Brian E. , Cangemi, David J. , Tack, Jan , Lunsford, Tisha N, Tack, Jan , Lacy, Brian E. , Crowell, Michael D. , Lunsford, Tisha , Simrén, Magnus

Mayo Clinic

American Journal of Gastroenterology | February 8, 2022 | Volume: 116 | Issue: 12 | Pages: 2345-2356

10.14309/ajg.0000000000001562 | PMID 35134012 Get It

Abstract: Disorders of gastric motor and sensory function affect 10%-20% of the world’s population and adversely impact nutrition, quality of life, work productivity, and health care costs. Classifying these disorders can be challenging given the heterogeneity of symptom presentation, the presence of symptoms unexplained by endoscopic, radiographic and/or laboratory evaluation, and overlap with other luminal gastrointestinal disorders. Accurately diagnosing these highly prevalent disorders relies upon an understanding of epidemiology and risk factors, the ability to take a careful clinical history focused on symptoms, and the presence of predisposing medical, surgical, and psychological conditions. A variety of diagnostic studies are now available to assess gastric motor function and identify maladaptive relaxation, accommodation, and abnormal sensation. FDA-approved treatment options are limited and thus many patients undergo a series of empirical treatment trials that target individual symptoms, often without much benefit. This article provides updated recommendations for identifying and classifying the most common gastric motor and sensory disorders using currently accepted diagnostic tests, and provides a brief supplemental overview on treatment options. “Things sweet to taste prove in digestion sour.” –Shakespeare, Richard II , 1595.
Left–Right Intensity Asymmetries Vary Depending on Scanner Model for FLAIR and T1 Weighted MRI Images
Arani, Arvin , Schwarz, Christopher G. , Wiste, Heather J. , Weigand, Stephen D. , Cogswell, Petrice M. , Murphy, Matthew C. , Trzasko, Joshua D. , Gunter, Jeffrey L. , Senjem, Matthew L. , McGee, Kiaran P. , Shu, Yunhong , Jack, Clifford R. , Initiative, the Alzheimer's Disease Neuroimaging, Bernstein, Matt A , Huston, John , Jack, Clifford R , Schwarz, Christopher G , Arani, Arvin , McGee, Kiaran , Senjem, Matthew L , Cogswell, Petrice M , Gunter, Jeffrey L , Bernstein, Matt A. , Huston, John , Initiative, the Alzheimer's Disease Neuroimaging

Mayo Clinic

Journal of Magnetic Resonance Imaging | February 8, 2022 | Volume: 56 | Issue: 3 | Pages: 917-927

10.1002/jmri.28105 | PMID 35133061 Get It

BackgroundLocalized regions of left–right image intensity asymmetry (LRIA) were incidentally observed on T2‐weighted (T2‐w) and T1‐weighted (T1‐w) diagnostic magnetic resonance imaging (MRI) images. Suspicion of herpes encephalitis resulted in unnecessary follow‐up imaging. A nonbiological imaging artifact that can lead to diagnostic uncertainty was identified.PurposeTo investigate whether systematic LRIA exist for a range of scanner models and to determine if LRIA can introduce diagnostic uncertainty.Study TypeA retrospective study using the Alzheimer's Disease Neuroimaging Initiative (ADNI) data base.SubjectsOne thousand seven hundred fifty‐three (median age: 72, males/females: 878/875) unique participants with longitudinal data were included.Field Strength3T.SequencesT1‐w three‐dimensional inversion‐recovery spoiled gradient‐echo (IR‐SPGR) or magnetization‐prepared rapid gradient‐echo (MP‐RAGE) and T2‐w fluid‐attenuated inversion recovery (FLAIR) long tau fast spin echo inversion recovery (LT‐FSE‐IR). Only General Electric, Philips, and Siemens' product sequences were used.AssessmentLRIA was calculated as the left–right percent difference with respect to the mean intensity from automated anatomical atlas segmented regions. Three neuroradiologists with 37 (**), 32 (**), and 3 (**) years of experience rated the clinical impact of 30 T2‐w three‐dimensional FLAIR exams with LRIA to determine the diagnostic uncertainty. Statistical comparisons between retrospective intensity normalized T1m and original T1‐w images were made.Statistical TestsFor each image type, a linear mixed effects model was fit using LRIA scores from all scanners, regions, and participants as the outcome and age and sex as predictors. Statistical significance was defined as having a P‐value <0.05.ResultsLRIA scores were significantly different from zero on most scanners. All clinicians were uncertain or recommended definite diagnostic follow‐up in 62.5% of cases with LRIA >10%. Individuals with acute brain pathology or focal neurologic deficits are not enrolled in ADNI; therefore, focal signal abnormalities were considered false positives.Data ConclusionLRIA is system specific, systematic, creates diagnostic uncertainty, and impacts IR‐SPGR, MP‐RAGE, and LT‐FSE‐IR product sequences.Level of Evidence: 2Technical Efficacy Stage: 3
Endovascular Therapy Versus Medical Therapy Alone for Basilar Artery Stroke: A Systematic Review and Meta‐Analysis Through Nested Knowledge
Pederson, John M. , Hardy, Nicole , Hutchison, Kristen , Heiferman, Daniel M. , Kallmes, David F. , Brinjikji, Waleed , Albers, Gregory W. , Heit, Jeremy J. , Kallmes, David, Heit, Jeremy J , Pederson, John M , Adusumilli, Gautam , Kallmes, Kevin M , Kobeissi, Hassan

Mayo Clinic

Stroke: Vascular and Interventional Neurology | February 8, 2022 | Volume: 2 | Issue: 3 | Pages: No page available

10.1161/svin.121.000147 | PMID 41583624 Get It

Background Endovascular thrombectomy (EVT) is an effective treatment for acute ischemic stroke attributable to the anterior circulation large‐vessel occlusion. Randomized trials of patients with posterior circulation large‐vessel occlusion (PC‐LVO) have failed to show a benefit of EVT over medical therapy (MEDT). We performed a systematic review and meta‐analysis to understand better whether EVT is beneficial for PC‐LVO. Methods Using the Nested Knowledge AutoLit living review platform, we identified randomized control trials and prospective studies that reported functional outcomes in patients with PC‐LVO treated with EVT versus MEDT. The primary outcome variable was 90‐day modified Rankin scale score of 0 to 3, and secondary outcome variables included 90‐day modified Rankin scale score of 0 to 2, 90‐day mortality, and rate of symptomatic intracranial hemorrhage. A separate random effects model was fit for each outcome measure to calculate pooled odds ratios. Results Three studies with 1248 patients, 860 in the EVT arm and 388 in the MEDT arm, were included in the meta‐analysis. The favorable outcome rate (modified Rankin scale score of 0–3) in patients undergoing EVT was 39.9% (95% CI, 30.6%–50.1%) versus 24.5% in patients undergoing MEDT (95% CI, 9.6%–49.8%). Patients undergoing EVT had higher modified Rankin scale score of 0 to 2 rates (31.8% [95% CI, 25.7%–38.5%] versus 19.7% [95% CI, 7.4%–42.7%]) and lower mortality (42.1% [95% CI, 35.9%–48.6%] versus 52.8% [95% CI, 33.3%–71.5%]) compared with patients undergoing MEDT, but neither result was statistically significant. Patients undergoing EVT were more likely to develop symptomatic intracranial hemorrhage (odds ratio, 10.36; 95% CI, 3.92–27.40). Conclusions EVT treatment of PC‐LVO trended toward superior functional outcomes and reduced mortality compared with MEDT despite a trend toward increased symptomatic intracranial hemorrhage in patients undergoing EVT. Existing randomized and prospective studies are insufficiently powered to demonstrate a benefit of EVT over MEDT in patients with PC‐LVO.
ABCD‐GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR‐PCI Trial
Angiolillo, Dominick J. , Lennon, Ryan J. , Goodman, Shaun G. , Kim, Sang‐Wook , O’Cochlain, Fearghas, So, Derek , Sweeney, John P., Rihal, Charanjit S. , Farkouh, Michael E. , Pereira, Naveen L. , Capodanno, Davide , Angiolillo, Dominick J , Lennon, Ryan J , Goodman, Shaun G , Kim, Sang-Wook , O'Cochlain, Fearghas, So, Derek Y , Sweeney, John , Rihal, Charanjit S. , Pereira, Naveen L

Mayo Clinic

Journal of the American Heart Association | February 8, 2022 | Volume: 11 | Issue: 4 | Pages: No page available

10.1161/jaha.121.024156 | PMID 35132875 Get It

Background In TAILOR‐PCI, genotype‐guided selection of P2Y 12 inhibitors after percutaneous coronary intervention did not significantly reduce the risk of ischemic events at 12 months. The Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping (ABCD‐GENE) score identifies patients with high platelet reactivity on clopidogrel at increased risk of ischemic events. The aim of this study was to investigate the value of the ABCD‐GENE score for tailoring P2Y 12 inhibitor selection after percutaneous coronary intervention. Methods and Results In a post hoc analysis of the TAILOR‐PCI, outcomes were analyzed by ABCD‐GENE score and allocation to genotype‐guided or conventional P2Y 12 inhibitor selection. Primary (death, myocardial infarction, or stroke) and secondary (cardiovascular death, myocardial infarction, stroke, stent thrombosis, or severe recurrent ischemia) outcomes were assessed. Among 3883 patients discharged on clopidogrel in the genotype‐guided and conventional therapy groups, 15.8% and 84.2% had high (≥10 points) or low (<10) ABCD‐GENE scores, respectively. At 12 months, both the primary (5.2% versus 2.6%, P <0.001) and secondary outcomes (7.7% versus 4.6%, P =0.001) were significantly increased in patients with high ABCD‐GENE score. Among 4714 patients allocated to genotype‐guided or conventional therapy, the former did not significantly reduce the 12‐month risk of the primary and secondary outcomes in both the high and low ABCD‐GENE score groups (p interaction =0.48 and 0.27, respectively). Conclusions Among patients with percutaneous coronary intervention on clopidogrel, the ABCD‐GENE score was helpful in identifying those at higher risk. The ABCD‐GENE score may potentially enhance the precision of tailored selection of P2Y 12 inhibitors, which needs to be confirmed in prospective investigations. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique Identifier: NCT01742117.
CELSR1 Risk Alleles in Familial Bicuspid Aortic Valve and Hypoplastic Left Heart Syndrome
Theis, Jeanne L. , Niaz, Talha , Sundsbak, Rhianna S., Fogarty, Zachary C. , Bamlet, William R. , Hagler, Donald J. , Olson, Timothy M. , Bamlet, William R , Fogarty, Zachary C , Theis, Jeanne L , Olson, Timothy M , Niaz, Talha

Mayo Clinic

Circulation: Genomic and Precision Medicine | February 8, 2022 | Volume: 15 | Issue: 2 | Pages: No page available

10.1161/circgen.121.003523 | PMID 35133174 Get It

Background: Whole-genome sequencing in families enables deciphering of congenital heart disease causes. A shared genetic basis for familial bicuspid aortic valve (BAV) and hypoplastic left heart syndrome (HLHS) was postulated. Methods: Whole-genome sequencing was performed in affected members of 6 multiplex BAV families, an HLHS cohort of 197 probands and 546 relatives, and 813 controls. Data were filtered for rare, predicted-damaging variants that cosegregated with familial BAV and disrupted genes associated with congenital heart disease in humans and mice. Candidate genes were further prioritized by rare variant burden testing in HLHS cases versus controls. Modifier variants in HLHS proband-parent trios were sought to account for the severe developmental phenotype. Results: In 5 BAV families, missense variants in 6 ontologically diverse genes for structural ( SPTBN1 , PAXIP1 , and FBLN1 ) and signaling ( CELSR1 , PLXND1 , and NOS3 ) proteins fulfilled filtering metrics. CELSR1 , encoding cadherin epidermal growth factor laminin G seven-pass G-type receptor, was identified as a candidate gene in 2 families and was the only gene demonstrating rare variant enrichment in HLHS probands ( P =0.003575). HLHS-associated CELSR1 variants included 16 missense, one splice site, and 3 noncoding variants predicted to disrupt canonical transcription factor binding sites, most of which were inherited from a parent without congenital heart disease. Filtering whole-genome sequencing data for rare, predicted-damaging variants inherited from the other parent revealed 2 cases of CELSR1 compound heterozygosity, one case of CELSR1 - CELSR3 synergistic heterozygosity, and 4 cases of CELSR1 - MYO15A digenic heterozygosity. Conclusions: CELSR1 is a susceptibility gene for familial BAV and HLHS, further implicating planar cell polarity pathway perturbation in congenital heart disease.
Patient engagement and advocacy considerations in development and implementation of a multicancer early detection program
Schear, Rebekkah , Hoyos, Jody , Davis, Anjee Q., Woods, Phylicia L., Poblete, Sung , Richardson, Robin N, Schear, Rebekkah M , Rutten, Lila J. Finney

Mayo Clinic

Cancer | February 8, 2022 | Volume: 128 | Issue: S4 | Pages: 909-917

10.1002/cncr.34047 | PMID 35133663 Get It

Advocacy organizations are poised to ensure that patients' needs and preferences inform the development, planning, and implementation of multicancer early detection technologies. Engaging patients and cancer advocacy organizations throughout the research, development, and implementation of multicancer early detection technologies is critical to optimize public health impact and health equity.